DARIC33

DARIC33 is an investigational, pharmacologically controlled, autologous chimeric antigen receptor T cell (CAR T) therapy that targets the myeloid cell surface antigen CD33. Developed using the proprietary Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) platform, this therapy enables external pharmacologic regulation of CAR T cell activity via rapamycin administration. At low, non-immunosuppressive concentrations of rapamycin, the DARIC33 CAR T cells become activated to recognize and kill CD33-expressing leukemia cells. Removal of rapamycin deactivates the CAR T cells, providing reversible, real-time control of T cell function. DARIC33 is under investigation primarily for relapsed or refractory acute myeloid leukemia (AML) in pediatric and young adult populations, with preclinical research for adult AML. The therapy aims to achieve potent anti-leukemia activity while limiting myeloid toxicity. The first-in-human study (PLAT-08) is led by Seattle Children’s Therapeutics in collaboration with Regeneron (after acquisition of the original developer, 2seventy bio) and was previously put on clinical hold due to a treatment-related fatal adverse event[1][2][3][4][5][6][8][10].

Brand names

SC-DARIC33SC-DARIC-33SC-DARIC 33

Other names

SC-DARIC33SC-DARIC-33SC-DARIC 33